MOXIDECTIN EGG REAPPEARANCE PERIODS
Tzelos , T. , Barbeito , J.S.G. , Nielsen , M.K. , Morgan , E.R. , Hodgkinson , J.E. & Matthews , J.B. ( 2017 ) Strongyle egg reappearance period after moxidectin treatment and its relationship with management fac- tors in UK equine populations . Veterinary Parasitology , 237 , 70 – 76 .
von Samson- Himmelstjerna , G. , Fritzen , B. , Demeler , J. , Schurmann , S. , Rohn , K. , Schnieder , T. et al. ( 2007 ) Cases of reduced cyatho- stomin egg- reappearance period and failure of Parascaris equo- rum egg count reduction following ivermectin treatment as well as survey on pyrantel efficacy on German horse farms . Veterinary Parasitology , 144 , 74 – 80 .
Continued from page 24
abdominal hernias in horses: a review of 21 cases . The Veterinary Quarterly , 16 , S108 – S110 .
Vilar , J.M. , Doreste , F. & Spinella , G. ( 2009 ) Double- layer mesh hernio- plasty for repair of incisional hernia in 15 horses . Journal of Equine Veterinary Science , 29 , 172 – 176 .
Whitfield- Cargile , C.M. , Rakestraw , P.C. , Hardy , J. et al. ( 2011 )
Comparison of primary closure of incisional hernias in horses with and without the use of prosthetic mesh support . Equine Veterinary Journal Supplement , 39 , 69 – 75 .
Wilderjans , H. & Meulyzer , M. ( 2022 ) Laparoscopic closure of the vag- inal rings in the standing horse using a tacked intraperitoneal slitted mesh (TISM) technique . Equine Veterinary Journal , 54 ( 2 ), 359 – 367 .
Continued from page 34
and prepared by N. A. Dodd and M. R. W. Smith assisted throughout. The manuscript was approved by both authors.
ACKNO WLE DGE MENTS We thank Adam Dodd for the spreadsheet guidance and the NEH team for the great compliance throughout the audit.
CONFLICT OF INTEREST STATEMENT The authors declare that they have no conflict of interest.
ETHICS STATEMENT Data were collected and recorded comprehensively in Excel. No names or horses are singled out. The study was conducted on the basis of improving retrospective data to apply best practices, the animal ' s health and care were not compromised at any point.
ORCID Natalie A. Dodd
https://orcid.org/0000-0003-4744-4269 Matthew R. W. Smith
https://orcid.org/0000-0002-8051-1534
REFERENCES
Esposito , P. & Dal Canton , A. ( 2014 ) Clinical audit, a valuable tool to im- prove quality of care: general methodology and applications in ne- phrology . World Journal of Nephrology , 3 ( 4 ), 249 – 255 .
Locke , E.A. & Latham , G.P. ( 2002 ) Building a practically useful theory of goal setting and task motivation . American Psychologist , 57 , 705 – 717 .
Menzies- Gow , N. ( 2017 ) Fluid therapy in horses– uses, types and admin- istration routes . Veterinary Times , 47 , 6 – 8 .
How to cite this article: Woodford , N. ( 2024 ) Improving your waistline, six pack or fit for purpose: Herniorrhaphy decisions . Equine Veterinary Education , 36 , 21 – 25 . Available from:
https://doi.org/10.1111/eve.13886
SUPPORTING INFORMATION Additional supporting information can be found online in the Supporting Information section at the end of this article.
| 41
How to cite this article: Mair , T.S. , Opie , R. , Moreton- Clack , M. , Parkin , T.D. & Matthews , J.B. ( 2024 ) Strongyle egg reappearance periods following moxidectin treatment in horses in Southeast England . Equine Veterinary Education , 36 , 36 – 41 . Available from:
https://doi.org/10.1111/eve.13848
How to cite this article: Dodd , N.A. & Smith , M.R.W. ( 2024 ) A clinical audit of the intravenous fluid therapy given to hospitalised horses . Equine Veterinary Education , 36 , 26 – 35 . Available from:
https://doi.org/10.1111/eve.13817
Advertisers’ Index
American Regent Animal Health ............... C2 Boehringer Ingelheim ................................ 8A CareCredit .................................................. 19 Cargill Animal Nutrition ............................ C4 Dechra Veterinary Products ........................ 25,C3
Kentucky Performance Products ............... 16A Merck Animal Health ................................ 16B PetVivo ...................................................... 35 Platinum Performance ............................... XIII Purina ........................................................ 8B
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76
